Scientists at the University of Texas at Austin have introduced an innovative experimental compound aimed at targeting cancer cells via dual metabolic pathways. This drug enhances glucose breakdown while concurrently inhibiting fatty-acid metabolism, leading to significant metabolic strain on cancer cells. In studies conducted on mice with aggressive melanoma, the treatment successfully eradicated the majority of cancer cells while exerting minimal impact on healthy cells. Additionally, laboratory assessments indicated efficacy against melanoma, leukemia, as well as breast, lung, liver, and neuroblastoma cancers. These discoveries are in preliminary stages, necessitating comprehensive testing prior to the commencement of human trials.
Disclosure: This video contains stock footage and content created or enhanced using Al-assisted tools.
ai-generated
